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Abstract
Background: Accumulated evidences indicate that single nucleotide polymorphisms (SNP) in angiogenesis and
tumorigenesis related genes are associated with risk of Hepatocellular carcinoma (HCC). COL18A1 encodes the precursor
of endostatin, which is a broad-spectrum angiogenesis inhibitor, and we speculate that SNPs in COL18A1 may be associated
with susceptibility to HCC.
Methods and Findings: We carried out a 2-stage association study in 3 independent case-control groups in a total of 1067
chronic hepatitis B (CHB) patients and 808 hepatitis B virus (HBV) related HCC patients in Han Chinese. Four SNPs which can
represent all potential functional SNPs with MAF.0.1 recorded in HapMap database were genotyped using TaqMan
methods. Levels of total COL18A1 mRNA were also examined using quantitative real-time RT-PCR. We found that rs7499
located in 39-UTR to be strongly associated with HBV related HCC (Pcombined=0.0000005, OR=0.72, 95%CI=0.63–0.82).
COL18A1 mRNA expression was significantly decreased as the disease progressed (P=0.000026).
Conclusion: These findings indicate that COL18A1 rs7499 may contribute to the risk of HCC in Han Chinese.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancy and ranks fifth in men and eighth in women among
causes of cancer mortality worldwide. It is estimated that about
564,000 new cases of HCC are reported throughout the world
each year [1]. Eastern Asia is the geographic area at highest risk of
HCC [1]. The cause of HCC is a complex interplay between
multiple genetic and environmental factors [2]. Hepatitis B virus
(HBV) and hepatitis C virus (HCV) are the main viral factors of
HCC, while in China, HBV related HCC is the most frequent. On
the other hand, accumulated evidences in molecular genetics
indicate that single nucleotide polymorphisms (SNP) in immune
response, angiogenesis and tumorigenesis related genes are
associated with susceptibility to HCC [3,4,5,6]. Recent progress
in genome-wide association study (GWAS) also have identified
new susceptibility loci for HCC [7,8].
Collagen, type XVIII, alpha 1 (COL18A1) gene locates at
21q22.3. It has 42 exons, and encodes a protein of 1336aa. This
protein is the precursor of endostatin, which is a 20-kDa protein
derived from carboxy-terminal proteolytic fragment of collagen
XVIII [9]. Endostatin is a broad-spectrum angiogenesis inhibitor
and interferes with growth factors such as VEGF [10], and has the
potency to inhibit neovascularization and tumor growth [11].
Angiogenesis plays an important role in tumorigenesis. Tumours
secrete a number of angiogenic growth factors such as VEGF.
Furthermore, the expression of endogenous inhibitors, for instance
endostatin and angiostatin, are downregulated [12]. Studies have
reported that endostatin expression was significantly stronger in
adjacent nontumor tissues than that in tumors in HCC specimen
[13], and effectively inhibit the growth of HCC [14].
According to the above evidence, we speculate that SNPs in
COL18A1 may be associated with susceptibility to HCC. We used
a candidate gene strategy and carried out a 2-stage association
study to confirm this hypothesis.
Materials and Methods
Subjects
The subjects enrolled in the present study included 3
independent case-control groups in a total of 1067 chronic
hepatitis B (CHB) patients and 808 HBV related HCC patients.
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patients enrolled from the 302 Hospital of the People’s Liberation
Army (Beijing) from Jan 2008 to Nov 2009. The second group
consisted of 326 HCC patients and 522 CHB patients enrolled
from Beijing Youan Hospital (Beijing) from Oct 2005 to Jul 2010.
The third group consisted of 313 HCC patients and 342 CHB
patients enrolled from Guangxi Cancer Hospital (Nanning,
Guangxi) from May 2005 to Jan 2008.
Controls were CHB patients whose serum levels of alanine
aminotransferase (ALT) and aspartate aminotransferase (AST)
were continuously .40 IU/L; they were HBsAg seropositive and
HBeAg seropositive for 6 months; their serum HBV DNA .2,000
copies/mL and confirmed by liver ultrasonography.
Cases were pathologically HCC patients, pathologically con-
firmed, and proved not to have other cancers. They were also
confirmed by liver ultrasonography and/or computed tomography.
Subjects were considered smokers if they smoked up to 6
months before the date of cancer diagnosis for HCC cases or the
date of interview for CHB controls. An alcohol drinker was
defined as someone who consumed alcohol at least once per week
for at least 6 months.
The subjects were excluded if: (1) there was evidence of past or
current infection with other hepatitis viruses or hepatitis not
caused by HBV; (2) they were not of Han ethnicity. The main
features of the subjects included are summarized in Table 1 and
Table S1. The study was carried out in accordance with the
guidelines of the Helsinki Declaration after obtaining written
informed consent from all the subjects and was approved by the
ethics committee of the Institute of Basic Medical Sciences,
Chinese Academy of Medical Sciences.
SNP selection and genotyping
Genomic DNA was extracted from peripheral blood by using a
salting-out protocol [15]. Using the HapMap database (HapMap
Data Rel 24/phase II Nov 08, on NCBI B36 assembly, dbSNP
b126), potential functional SNPs (SNPs in promoter region and
mRNA sequence) with minor allele frequency (MAF) of greater
than 0.10 for the Han Chinese Beijing population were selected
from the entire gene region from approximately 4000 bp upstream
of the transcription start site to 2000 bp downstream of the
39untranslated region (39UTR). Five SNPs were found, namely
rs2183589 (promoter), rs2230687, rs2230688, rs11702425 (syn-
onymous coding) and rs7499 (39UTR). Among these SNPs,
rs2230687 and rs2230688 were in complete linkage disequilibrium
(LD) according to HapMap data, so we chose rs2230688 as a
representative. The 4 selected SNPs were genotyped by TaqMan
method, with probes synthesized by Sangon BioTech Co Ltd
(Shanghai, China). Primers and TaqMan probes used are listed in
Table S2. All the samples were successfully genotyped. For
genotyping quality control, 5% samples were randomly selected
and directly sequenced, and we obtained 100% identical results.
Quantitative Analysis of Gene Expression
Total RNA was extracted from the peripheral blood by RNAprep
pure Blood Kit (TianGen, Beijing, China). cDNA was synthesize in a
20 uL reaction volume containing Oligo (dT)18 primers (MBI
Fermentas, Lithuania), and RevertAid
TM H minus M-MuLV reverse
transcriptase (MBI Fermentas, Lithuania). Expression of COL18A1
mRNA was measured by TaqMan relative quantitative analysis using
the Bio-Rad iQ5 Real-Time PCR Detection system (Bio-Rad,
Hercules, CA). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an internal control gene. The primers and
probe used for amplification of COL18A1 and GAPDH cDNA
samples are listed in Table 2. The amplifications of COL18A1 and
GAPDH cDNA of each sample were performed in the same 96-well
PCR plate. Each experiment was performed in triplicate assay. The
comparative Ct (2
2DDCt) method was employed to quantify
COL18A1 expression as described previously [16].
Table 1. Clinical features of the subjects included in the study.
302_Beijing Youan_Beijing Guangxi
HCC CHB P HCC CHB P HCC CHB P
Number 169 203 326 522 313 342
Age, y 50 (42, 55) 49 (38, 57) 0.37
a 52 (45, 58) 40 (34, 49) ,0.001
a 43 (37, 51) 41 (35, 52) 0.10
a
Gender (male/female) 143/26 158/45 0.10
b 270/56 379/143 ,0.001
b 280/33 283/59 0.01
b
Smoking (Yes/No) 84/85 64/139 ,0.001
b 135/159 103/378 ,0.001
b 128/185 141/201 0.93
b
Drinking (Yes/No) 93/76 71/132 ,0.001
b 141/153 113/366 ,0.001
b 95/218 97/245 0.58
b
Family history of HBV (Yes/No) 98/71 133/70 0.14
b 141/172 333/169 ,0.001
b
Family history of HCC (Yes/No) 52/261 16/326 ,0.001
b
HbeAg (+/2) 65/104 131/72 ,0.001
b 128/198 356/166 ,0.001
b
ALT (IU/L) 218 (67, 227) 227 (113, 268) ,0.001
a 129 (109, 142) 131 (122, 143) 0.01
a
AST (IU/L) 158 (72, 230) 160 (96, 245) 0.03
a 124 (108, 165) 125 (109, 162) 0.88
a
TBil (mmol/L) 36 (19, 49) 34 (21, 50) 0.08
a 49 (28, 61) 39 (22, 54) ,0.001a
DBil (mmol/L) 28 (15, 35) 29 (15, 36) 0.89
a 33 (16, 50) 27 (11, 35) ,0.001
a
Log HBV-DNA (copy/mL) 5.9 (4.6, 6.2) 6.7 (5.5, 7.2) ,0.001
a 5.4 (4.6, 6.0) 5.6 (4.7, 6.1) ,0.001
a
Age, ALT, AST, TBil, DBil, and HBV-DNA as median (25-percentile, 75-percentile).
HCC: hepatocellular carcinoma.
CHB: chronic hepatitis B.
aMann-Whitney U test.
bChi-square test.
doi:10.1371/journal.pone.0033855.t001
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By using the x2 test, we tested whether the genotype
distributions for the studied SNP were in the Hardy-Weinberg
equilibrium (HWE). We used 262o r2 63 contingency tables for
comparing allele and genotype frequencies between groups. Tests
for differences of quantitative traits and COL18A1 mRNA
expression between different groups were performed using the
Mann-Whitney U test or Kruskal-Wallis Test for traits with
nonnormal distributions, or ANOVA for normally distributed
traits. P,0.05 was the criterion for statistical significance. All
statistical analyses were performed using the Statistical Package for
the Social Sciences (SPSS), version 12.0. We obtained estimates of
LD values (r2, D9) and the haplotype estimation using the SHEsis
online software [17].
Results
We first conducted genotyping experiments for the 4 COL18A1
polymorphisms in the 302_Beijing group of samples. Genotype
distributions of the studied SNPs were in HWE in both cases and
controls. The genotype distributions and allelic frequencies of
COL18A1 polymorphisms in CHB and HCC patients were
represented in Table 2. The frequency of C allele of rs7499 was
45.3% in HCC patients vs. 55.4% in CHB patients (P=0.006,
OR=0.67, 95%CI=0.50–0.89). The Cochran-Armitage trend
test (assuming an additive model for C allele) revealed an allele
dose-dependent association of rs7499 with the HCC (P=0.005),
with increased OR of 2.08 and 2.38 for CT and TT genotypes,
respectively. We then used binary logistic regression to adjust for
confounding factors as age, gender, smoking and drinking under
additive model, and the result showed that rs7499 was still
independently associated with HCC (P=0.009, OR=0.66,
95%CI=0.48–0.90). The 3 other SNPs, however, were not
associated with HCC under any model. We analyzed the degree of
LD for these 4 SNPs, and found there was no apparent LD
(D9#0.291, r
2#0.017). Table 3 shows 5 common haplotypes
constructed by these 4 SNPs. The C-T-T-T haplotype was
associated with HCC most significantly (P=0.0002). Notably, the
C-T-T-C haplotype, which was different with C-T-T-T haplotype
only at the rs7499 locus, was also associated with HCC (P=0.01),
but with opposite tendency. These results were in accordance with
the single locus analysis, suggesting that rs7499 was a principal
genetic factor in COL18A1.
We next replicated genotyping of rs7499 in 2 independent case-
control samples from Beijing and Guangxi respectively. The result
was presented in Table 4. rs7499 was associated with HCC
significantly both with the same tendency as the first group of
samples. Except that in group 2, when using binary logistic
regression to adjust age, gender, smoking and drinking, the
association was disappeared (P=0.29). We combined the 3
groups together, in a total of 1067 CHB patients and 808 HCC
patients, the frequency of C allele of rs7499 was 42.5% in HCC
patients vs. 50.8% in CHB patients (P=0.0000005, OR=0.72,
95%CI=0.63–0.82). The Cochran-Armitage trend test and
binary logistic regression also indicated rs7499 to be strongly
associated with HCC (P=0.0000004, P=0.00001, respectively).
We examined the quantitative traits such as ALT, AST, total
bilirubin (TBil), direct bilirubin (DBil) and HBV DNA levels with
different genotypes among CHB and HCC patients respectively to
evaluate the association between genotypes of SNP rs7499 and
phenotypes. The results showed that the quantitative traits did not
Table 2. Genotype distributions of 4 SNPs in COL18A1 gene of the 302_Beijing samples.
Allele, n (%)
Genotype, n
(%)
Cochran
Armitage
trend test
logistic
regression
#
1/2 1 2 P/OR (95% CI) 11 12 22 P P/OR (95% CI)
rs2183589 C/T
HCC (n=169) 306 (90.5%) 32 (9.5%) 0.18 139 (82.2%) 28 (16.6%) 2 (1.2%) 0.18 0.20
CHB (n=203) 355 (87.4%) 51 (12.6%) 1.37 (0.86–2.19) 155 (76.4%) 45 (22.2%) 3 (1.5%) 1.37 (0.85–2.22)
rs2230688 G/T
HCC (n=169) 223 (66.0%) 115 (34.0%) 0.43 72 (42.6%) 79 (46.7%) 18 (10.7%) 0.43 0.41
CHB (n=203) 279 (68.7%) 127 (31.3%) 0.88 (0.65–1.20) 99 (48.8%) 81 (39.9%) 23 (11.3%) 0.88 (0.64–1.20)
rs11702425 T/C
HCC (n=169) 262 (77.5%) 76 (22.5%) 0.98 104 (61.5%) 54 (32.0%) 11 (6.5%) 0.98 0.73
CHB (n=203) 315 (77.6%) 91 (22.4%) 0.99 (0.70–1.41) 127 (62.6%) 61 (30.0%) 15 (7.4%) 0.94 (0.67–1.32)
rs7499 C/T
HCC (n=169) 153 (45.3%) 185 (54.7%) 0.006 29 (17.2%) 95 (56.2%) 45 (26.6%) 0.005 0.009
CHB (n=203) 225 (55.4%) 181 (44.6%) 0.67 (0.50–0.89) 63 (31.0%) 99 (48.8%) 41 (20.2%) 0.66 (0.48–0.90)
#P values were adjusted for age, gender, smoking and drinking by binary logistic regression.
doi:10.1371/journal.pone.0033855.t002
Table 3. Common haplotypes constructed with SNPs
rs2183589, rs2230688, rs11702425 and rs7499 in COL18A1
gene of the 302_Beijing samples.
Haplotypes HCC (n=169) CHB (n=203) P OR (95%CI)
C-G-C-T 42.84 (12.7%) 24.33 (6.0%) 0.003 2.20 (1.31–3.71)
C-G-T-C 77.97 (23.1%) 113.98 (28.1%) 0.06 0.73 (0.52–1.02)
C-G-T-T 63.69 (18.8%) 76.35 (18.8%) 0.82 0.96 (0.66–1.39)
C-T-T-C 24.70 (7.3%) 51.37 (12.7%) 0.01 0.52 (0.31–0.86)
C-T-T-T 68.67 (20.3%) 40.61 (10.0%) 0.0002 2.22 (1.46–3.39)
others 60.13 (17.8%) 99.36 (24.5%)
doi:10.1371/journal.pone.0033855.t003
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shown).
We then examined levels of total COL18A1 mRNA using
quantitative real-time RT-PCR. Expression of COL18A1 mRNA
levels was measured in RNA from WBCs in 20 HCC patients, 32
CHB patients and 43 HBsAg-negative healthy individuals.
Expression levels of COL18A1 mRNA for the three different
genotypes of rs7499 were also compared in CHB patients and
HBsAg-negative healthy individuals. Final abundance figures were
adjusted to yield an arbitrary value of 1 for HCC patients
(Figure 1A). The result showed that the HBsAg-negative healthy
individuals had 2.33-fold higher COL18A1 mRNA expression
than HCC patients and CHB patients had 1.79-fold higher
COL18A1 mRNA expression than HCC patients (P=0.000026).
The COL18A1 mRNA level between three different genotypes of
rs7499 in healthy individuals had no significant differences (CC:
1.8160.75; CT: 2.3961.23; TT: 2.4661.22; P=0.60). But in
CHB patients, TT carriers had significant lower COL18A1
mRNA level than non-TT carriers (1.1860.67 vs. 2.0361.08,
P=0.035), as shown in Figure 1B.
Discussion
As an anti-angiogenesis gene, COL18A1 plays an important
role in tumorigenesis. Studies have reported that SNPs in
COL18A1 are associated with numerous cancers, such as breast
cancer [18,19], prostate carcinoma [20,21], colorectal adenocar-
cinoma [22] and lung cancer [23]. A non synonymous SNP,
D104N, located in the 42th exon of COL18A1, is widely studied
[18,19,20,21,22,23]. However, the MAF of this SNP is low in
HCB population, about 0.047 according to HapMap data, as we
selected SNPs with MAF.0.1, the D104N polymorphism was not
included in the present study. Further studies are needed to
elucidate the role of D104N in HCC.
The distribution of gene polymorphism differed greatly in
different ethnicity and region. In the present study, we collected
samples from south and north of China, which may represent the
population differences. The genotype distribution of rs7499
between Beijing and Guangxi population is different (Table 2
and Table 4); however, the tendency of differences between CHB
and HCC groups is similar. The association between rs7499 and
HCC has been replicated in both Beijing and Guangxi
populations, which indicates that this polymorphism may have a
genetic influence in the development of HCC.
rs7499 locates in the 39-UTR region. After retrieving the NCBI
dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_gf.cgi), we
find that rs7499 is in complete LD with another two 39-UTR SNPs,
i.e. rs8199 and rs7867. SNPs in 39-UTR region may disrupt or create
a microRNA binding site so as to repress translation or destabilize
mRNA. The ‘‘C’’ to ‘‘T’’ change of rs7499 may disrupt a binding site
for a microRNA hsa-mir-328. The analysis was performed with the
program miRBase, available at http://www.mirbase.org/index.shtml
[24]. These data indicate that rs7499 may be functional itself,or in LD
with other functional SNPs. Several recent works have also genotyped
rs7499 and studied its association with myopia [25] and ovarian
cancer [26]. Interestingly, in these studies, rs7499 were not associated
with diseases, but the distribution patterns of different genotypes of
rs7499 were similar in different populations.
We examined the COL18A1 mRNA expression and find that the
HBsAg-negative healthy individuals and CHB patients had higher
mRNA expression than HCC patients. The role of Endostatin/
collagen XVIII expression during HCC was controversial [27,28,29].
Evidences suggested that free, soluble endostatin inhibited angiogen-
esis, whereas immobilized form supported the survival and migration
of endothelial cells; so in some cases, endostatin/C18 may promote,
instead of abolish, angiogenic processes [30,31]. The present results
suggest that since the expression of angiogenesis factors is elevated
during HCC tumorigenesis, it is reasonable that expression of
angiogenesis inhibitors such as endostatin/C18 is decreased in HCC
p a t i e n t s .W ea l s oc o m p a r et h eC O L 1 8 A 1m R N Ae x p r e s s i o nb e t w e e n
three different genotypes of rs7499 in HBsAg-negative healthy
individuals and CHB patients. The results in CHB patients showed
that TT carriers had significant lower COL18A1 mRNA level than
non-TT carriers, but in HBsAg-negative healthy individuals, CO-
L18A1 mRNA level between 3 genotypes did not differed significantly.
There is possibility that rs7499 genotypes were not directly associated
with COL18A1 mRNA expression. For the gene expression regulation
is complicated. The role of endostatin expression during HCC was
controversial, in some cases, endostatin may promote, instead of
abolish, angiogenic processes. On the other hand, the samples for
studying gene expression are small, so there is possibility of false
negative. The result should be verified in larger sample set.
Table 4. Association results for rs7499 in replication studies.
Allele, n (%)
Genotype, n
(%)
Cochran
Armitage
trend test
logistic
regression
#
C T P/OR (95% CI) CC CT TT P P/OR (95% CI)
Youan_Beijing
HCC (n=326) 297 (45.6%) 355 (54.4%) 0.003 63 (19.3%) 171 (52.5%) 92 (28.2%) 0.003 0.29
CHB (n=522) 552 (52.9%) 492 (47.1%) 0.75 (0.61–0.91) 151 (28.9%) 250 (47.9%) 121 (23.2%) 0.88 (0.70–1.11)
Guangxi
HCC (n=313) 237 (37.9%) 389 (62.1%) 0.01 41 (13.1%) 155 (49.5%) 117 (37.4%) 0.01 0.01
CHB (n=342) 307 (44.9%) 377 (55.1%) 0.75 (0.60–0.93) 70 (20.5%) 167 (48.8%) 105 (30.7%) 0.75 (0.60–0.94)
Combined
*
HCC (n=808) 687 (42.5%) 929 (57.5%) 5e-7 133 (16.5%) 421 (52.1%) 254 (31.4%) 4e-7 0.00001
CHB (n=1067) 1084 (50.8%) 1050 (49.2%) 0.72 (0.63–0.82) 284 (26.6%) 516 (48.4%) 267 (25.0%) 0.73 (0.64–0.84)
#P values were adjusted for age, gender, smoking and drinking by binary logistic regression.
*Combination of 3 case-control samples from 302_Beijing, Youan_Beijing and Guangxi.
doi:10.1371/journal.pone.0033855.t004
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clinical features between CHB and HCC patients did not match well.
Especially in the Youan_Beijing group of samples, when adjusting
age, gender, smoking and drinking, the association between rs7499
and HCC is disappeared. In future studies, clinical features should be
well matched. Second, the selection of SNPs in our work is based on
database searching. Although the 4 SNPs genotyped in our work can
represent all potential functional SNPs with MAF.0.1 recorded in
HapMap database, it should be noted that some SNPs not recorded
in the database may be omitted; sequencing the whole functional
region of COL18A1 is needed in future studies.
In conclusion, we carried out a 2-stage association study and
found rs7499 located in 39-UTR region of COL18A1 gene to be
strongly associated with HBV related HCC. Further study in other
ethnicities, and the present finding to be confirmed with larger
sample set in Han Chinese will be needed to clarify the role of this
polymorphism.
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Figure 1. Quantification of COL18A1 mRNA expression by real-time PCR. GAPDH was used as an internal control gene. Final abundance
figures were adjusted to yield an arbitrary value of 1 for HCC patients. Each experiment was performed in triplicate assay. Data are means6SD. A.
COL18A1 mRNA expression in HCC, CHB, and healthy individuals. B. COL18A1 mRNA expression in CHB patients, among different genotypes of
rs7499.
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